Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Iptacopan in C3G and IC-MPGN
NCT03955445Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- May 2036
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, open-label trial of Iptacopan in Complement 3 glomerulopathy (C3G) and idiopathic immune complex membranoproliferative glomerulonephritis (IC-MPGN) (6 cohorts), sponsored by Novartis. Primary endpoints: Composite renal endpoint at 9 months, C3 Deposit Score at 9 months and 3 more. Started Oct 2019; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)idiopathic immune complex membranoproliferative glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT03955445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955445.